Schering and US partner TAP Pharmaceuticals have stopped giving the uterine fibroid drug asoprisnil to patients in a late-stage trial after reporting adverse side effects. The companies, which had already delayed an expected 2005 NDA filing on the drug, now say that they don't know when they may file. A spokesman for Schering said that they would discuss the trial results with regulators before deciding how to proceed or giving a new time line for an NDA. Schering had been banking on the drug--used to treat uterine bleeding and shrink benign growths--to improve its financial performance.
- read this report from AFX for more